Brief: Cytodyn Receives Positive DSMC Recommendation For Leronlimab Phase 3 Covid-19 Trial With No Safety Concerns
04/08/2020 22:27
Aug 4 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN RECEIVES POSITIVE DSMC RECOMMENDATION FOR
LERONLIMAB
PHASE 3 COVID-19 TRIAL WITH NO SAFETY CONCERNS
Source text for Eikon: ID:nGNX2HpgLM
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer